Evidence map›Paper›PMID 30801977›Full record

ArticleAmerican journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics2019

Population-based identity-by-descent mapping combined with exome sequencing to detect rare risk variants for schizophrenia.

Denise Harold, Siobhan Connolly, Brien P Riley, Kenneth S Kendler, Shane E McCarthy, William R McCombie, Alex Richards, Michael J Owen, Michael C O'Donovan, James Walters and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Rare compound heterozygous missenseNeuropsychiatric disease and treatment · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Denise HaroldNeuropsychiatric Genetics Research Group, Institute of Molecular Medicine and Discipline of Psychiatry, Trinity College Dublin, Dublin, Ireland.
Siobhan ConnollyNeuropsychiatric Genetics Research Group, Institute of Molecular Medicine and Discipline of Psychiatry, Trinity College Dublin, Dublin, Ireland.
Brien P RileyDepartments of Psychiatry and Human Genetics, Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia.
Kenneth S KendlerDepartments of Psychiatry and Human Genetics, Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, Virginia.ORCID 0000-0001-8689-6570
Shane E McCarthyThe Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
William R McCombieThe Stanley Institute for Cognitive Genomics, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York.
Alex RichardsMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, United Kingdom.
Michael J OwenMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, United Kingdom.
Michael C O'DonovanMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, United Kingdom.
James WaltersMRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, United Kingdom.
Wellcome Trust Case Control Consortium 2
Schizophrenia Working Group of the Psychiatric Genomics Consortium
Gary DonohoeCognitive Genetics and Cognitive Therapy Group, Neuroimaging, Cognition & Genomics (NICOG) Centre & NCBES Galway Neuroscience Centre, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Galway, Ireland.ORCID 0000-0003-3037-7426
Michael GillNeuropsychiatric Genetics Research Group, Institute of Molecular Medicine and Discipline of Psychiatry, Trinity College Dublin, Dublin, Ireland.
Aiden CorvinNeuropsychiatric Genetics Research Group, Institute of Molecular Medicine and Discipline of Psychiatry, Trinity College Dublin, Dublin, Ireland.
Derek W MorrisCognitive Genetics and Cognitive Therapy Group, Neuroimaging, Cognition & Genomics (NICOG) Centre & NCBES Galway Neuroscience Centre, School of Psychology and Discipline of Biochemistry, National University of Ireland Galway, Galway, Ireland.ORCID 0000-0002-3413-570X
Cardiff University · GBTrinity College Dublin · IECold Spring Harbor Laboratory · USOllscoil na Gaillimhe – University of Galway · IEVirginia Commonwealth University · US

Funding

Genomic Psychiatry CohortR01MH085548 · NIMH · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PATO, CARLOS N, PATO, MICHELE T · 2008 to 2012
$16.3M
THE GENETIC EPIDEMIOLOGY OF SCHIZOPHRENIA IN IRELANDR01MH041953 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI KENDLER, KENNETH SEEDMAN · 1987 to 2008
$5.2M
A genome-wide association study of schizophrenia in IrelandR01MH083094 · NIMH · VIRGINIA COMMONWEALTH UNIVERSITY · PI RILEY, BRIEN P · 2008 to 2011
$3.5M
6/7 Psychiatric Genomics Consortium finding actionable variationU01MH109499 · NIMH · TRINITY COLLEGE DUBLIN · PI CORVIN, AIDEN PETER · 2016 to 2020
$772k
6/7 Psychiatric Genomics Consortium: Advancing Discovery and ImpactR01MH124875 · NIMH · TRINITY COLLEGE DUBLIN · PI Aiden Peter Corvin · 2021 to 2026
$765k
Medical Research Council MR/L010305/1Medical Research Council MR/P005748/1NIMH NIH HHS R01 MH041953NIMH NIH HHS R01 MH083094NIMH NIH HHS R01 MH085548NIMH NIH HHS R01 MH124875NIMH NIH HHS U01 MH109499Science Foundation Ireland 08/IN.1/B1916Science Foundation Ireland 12/IP/1359Science Foundation Ireland 12/IP/1670Wellcome TrustWellcome Trust 085475/B/08/Z
6 · The paper itself

Abstract

Genome-wide association studies (GWASs) are highly effective at identifying common risk variants for schizophrenia. Rare risk variants are also important contributors to schizophrenia etiology but, with the exception of large copy number variants, are difficult to detect with GWAS. Exome and genome sequencing, which have accelerated the study of rare variants, are expensive so alternative methods are needed to aid detection of rare variants. Here we re-analyze an Irish schizophrenia GWAS dataset (n = 3,473) by performing identity-by-descent (IBD) mapping followed by exome sequencing of individuals identified as sharing risk haplotypes to search for rare risk variants in coding regions. We identified 45 rare haplotypes (>1 cM) that were significantly more common in cases than controls. By exome sequencing 105 haplotype carriers, we investigated these haplotypes for functional coding variants that could be tested for association in independent GWAS samples. We identified one rare missense variant in PCNT but did not find statistical support for an association with schizophrenia in a replication analysis. However, IBD mapping can prioritize both individual samples and genomic regions for follow-up analysis but genome rather than exome sequencing may be more effective at detecting risk variants on rare haplotypes.

Indexed as

AdultCase-Control StudiesChromosome MappingDatabases, GeneticDNA Copy Number VariationsExomeExome SequencingFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyGenotypeHaplotypesHumansMaleMiddle AgedRisk FactorsGWASIBD mappingrare variants

Identifiers

PMID30801977
PMCPMC8863274
OpenAlexW2915164847

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.